BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial - Taiwan

A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee

The purpose of this trial is to evaluate the safety and effectiveness of the Biphasic Cartilage Repair Implant (BiCRI) compared to marrow stimulation in the treatment of chondral and osteochondral lesions located on the medial femoral condyle, lateral femoral condyle, or trochlea of the knee. The hypothesis is that the BiCRI provides an improvement in pain and function as compared to baseline, that is no worse than marrow stimulation at 1 year.

Study Overview

• Status: Completed
• Conditions: Chondral or Osteochondral Lesion of Medial Femoral Condyle; Chondral or Osteochondral Lesion of Lateral Femoral Condyle; Chondral or Osteochondral Lesion of Trochlea
• Intervention / Treatment: Device: BiPhasic Cartilage Repair Implant; Procedure: Marrow Stimulation

• Study Type: Interventional
• Enrollment (Actual): 92
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Changhua, Taiwan
    • Show Chwan Memorial Hospital (SCMH)
  • Kaohsiung, Taiwan
    • Chang Gung Memorial Hospital Kaohsiung (CGMH-KS)
  • Linkou, Taiwan
    • Chang Gung Memorial Hospital Linkou (CGMH-LK)
  • Taichung, Taiwan
    • China Medical University Hospital (CMUH)
  • Taichung, Taiwan
    • Veterans General Hospital Taichung (VGHTC)
  • Tainan, Taiwan
    • National Cheng Kung University Medical Center (NCKUMC)
  • Taipei, Taiwan
    • National Taiwan University Hospital (NTUH)
  • Taipei, Taiwan
    • Shuang Ho Hospital (SHH)
  • Taipei, Taiwan
    • Taipei Tzu Chi Hospital (TTCH)
  • Taipei, Taiwan
    • Tri-Service General Hospital (TSGH)
  • Taipei
    • Taipei county, Taipei, Taiwan
      • Taipei Medical University-Shuang Ho Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 55 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

1. Male or female presenting with a single, symptomatic chondral or osteochondral lesion of the medial or lateral femoral condyles or the trochlea requiring primary surgical intervention
2. Skeletally mature (epiphyses are confirmed to be closed on x-ray)
3. ICRS grade 3-4 lesion, Outerbridge grade 4, or OCD grades 3-4

4. Lesion size requires no more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion size will be assessed at the time of the study procedure for all subjects. If the size of the lesion is appropriate for 1 or 2 implants the patient will be randomized. If the lesion is found to be too large the patient will not be included in the trial, but will be treated according to standard of care. Lesion sizes that are considered appropriate include the following:

   • Lesion is 3mm x 3mm or larger and can be completely covered by the small (12.5mm diameter) sizer (excluding small fissures). This lesion should be treated with 1 implant. or
   • Lesion is 3mm x 3mm or larger and cannot be covered by the small sizer, but can be completely covered by the large (oval shaped) sizer (excluding small fissures). This lesion should be treated with 2 implants.
5. Willing and able to refrain from taking pain medications (including: narcotic and non-steroidal anti-inflammatory drugs) for 7 days prior to the baseline preoperative visit and for 7 days prior to the 12-month postoperative visit (i.e., a "wash out" period)
6. Willing and able to return for follow-up over a one year post-operative period
7. Willing and able to comply with all postoperative guidelines

Exclusion Criteria

1. ≥ 55 years old
2. Lesions > grade II on the articular surface of the tibia or patella
3. Kissing lesions (defined as an opposing lesion > grade II on the surface of the tibia or patella). Lesion ≤ grade II on opposing surface would be acceptable.
4. Prior surgical treatment of the lesion

5. Lesion would require more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion sizes that are not considered appropriate include the following:

   • Lesion is smaller than 3mm x 3mm
   • Lesion cannot be completely covered by the large sizer
6. Lesion will require bone grafting
7. Rheumatoid arthritis and other inflammatory arthritis

8. Concomitant comorbidities, such as:

   • ACL instability that will not be corrected before or during the study procedure ("ACL instability" defined as the presence of a positive "pivot shift" test)
   • Significant knee instability that will not be corrected before or during the study procedure

   • Significant malalignment (varus or valgus deformity, patellar malalignment) that will not be corrected before or during the study procedure. Significant malalignment defined as:

     • Any joint space narrowing as compared to the same compartment in the contralateral knee.
     • Mechanical axis alignment outside the tibial spines.
     • Patellofemoral subluxation on sunrise view.
     • History of patellar dislocation or subluxation.
   • Severe meniscal damage ("Severe meniscal damage" defined as > 50% of the meniscus missing or a radial tear extending to the meniscal-synovial junction)

   • Knee stiffness, defined as:

     • Flexion contracture >10°
     • Flexion degree < 115°
9. Body Mass Index (BMI) > 35.0
10. Local or systemic infection, not including asymptomatic urinary tract infection if treated with antibiotics preoperatively
11. Pregnancy or breast feeding
12. Prisoner
13. Patient is involved in a personal litigation (e.g. Worker's Compensation lawsuit) that relates to their knee surgery
14. Patient is actively participating in another medical device, drug, or biologic investigation (active defined as within the last 30 days)
15. Patient otherwise meets the study criteria but refuses to consent in writing to participate in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BiCRI; BiPhasic Cartilage Repair Implant	Device: BiPhasic Cartilage Repair Implant; 1 or 2 BiCRI devices, depending on lesion size
Active Comparator: Marrow Stimulation; Microfracture or Subchondral Drilling	Procedure: Marrow Stimulation; Microfracture or Subchondral Drilling

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IKDC-2000 Subjective Knee Evaluation	Subjective evaluation of knee pain and function (will be captured at preop and each postop visit through 12 months)	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IKDC-2000 Knee Examination Form	Objective evaluation of knee pain and function	Preop, 6 weeks, 3 months, 6 months, and 12 months
IKDC-2000 Current Health Assessment Form	Subjective evaluation of quality of life (QOL) and activities of daily living (ADL)	Preop, 6 weeks, 3 months, 6 months, and 12 months
Knee Injury and Osteoarthritis Outcome Score (KOOS)	A subjective instrument to assess the subject's opinion about their knee and associated problems	Preop, 6 weeks, 3 months, 6 months, and 12 months
Pain (VAS): sitting, standing, and squatting	Subjective evaluation of pain during routine activities	Preop, 6 weeks, 3 months, 6 months, and 12 months
Magnetic Resonance Imagining (MRI)	MRI to evaluate cartilage and bone condition	Preop and 12 months
Radiographs	Not all views taken at each time frame.; Weight bearing full extension AP view (both knees); Rosenberg view (45 degree PA flexion weight bearing, both knees); Lateral view of involved knee; Sunrise (skyline) view of involved knee	Preop, immediate postop, 6 weeks, 3 months, 6 months, 12 months
Adverse Events	Documentation of all adverse events from treatment through the end of the study.	Treatment through 12 months
Arthroscopy with biopsy	Arthroscopic second look to visualize the repair site. Biopsy of the cartilage and bone region of the treated site. Only performed on patients who agree to second procedure.	12 months

Collaborators and Investigators

• Sponsor: BioGend Therapeutics Co.Ltd
• Investigators: Study Director: Gwen Chang, MS, BioGend Therapeutics Co.Ltd

Study record dates

Study Major Dates

• Study Start: October 1, 2011
• Primary Completion (Actual): April 1, 2019
• Study Completion (Actual): August 1, 2019

Study Registration Dates

• First Submitted: November 14, 2011
• First Submitted That Met QC Criteria: November 18, 2011
• First Posted (Estimate): November 22, 2011

Study Record Updates

• Last Update Posted (Actual): January 20, 2022
• Last Update Submitted That Met QC Criteria: January 18, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Knee; Autologous; Medical device; Cartilage repair; Cartilage regeneration; Chondral; Osteochondral; Biphasic scaffold; Synthetic; Medial condyle; Lateral condyle; Trochlea
• Other Study ID Numbers: CR09-006; 9907776 (Other Identifier: Taiwan FDA - IDE #)